# Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

> **NCT00040768** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00040768
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-04
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040768, "Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00040768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*